This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Pipenzolate is an antimuscarinic agent indicated in the treatment of gastrointestinal motility disorders and arrhythmia.

Generic Name
Pipenzolate
DrugBank Accession Number
DB13844
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 354.469
Monoisotopic: 354.206370186
Chemical Formula
C22H28NO3
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-Benzodiazepine1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
AclidiniumThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Pipenzolate.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
AlfentanilThe risk or severity of adverse effects can be increased when Pipenzolate is combined with Alfentanil.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Pipenzolate.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Pipenzolate bromideJPX41DUS2B125-51-9XEDCWWFPZMHXCM-UHFFFAOYSA-M
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ASILON SUSPANSIYON 100 ML SUSPANSIYONPipenzolate bromide (4 mg/5ml) + Simethicone (40 mg/5ml)SuspensionAKDENİZ İLAÇ SAN. VE TİC. A.Ş.2020-08-14Not applicableTurkey flag
LIBKOL FILM TABLET, 20 TABLETPipenzolate (2.5 mg) + Chlordiazepoxide (5 mg)Tablet, film coatedSABA İLAÇ SAN. VE TİC. A.Ş.2020-08-142018-09-27Turkey flag
LIBKOL FILM TABLET, 50 ADETPipenzolate (2.5 mg) + Chlordiazepoxide (5 mg)Tablet, film coatedSABA İLAÇ SAN. VE TİC. A.Ş.2020-08-142018-09-27Turkey flag

Categories

ATC Codes
A03CA09 — Pipenzolate and psycholepticsA03AB14 — Pipenzolate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Piperidines / Tetraalkylammonium salts / Tertiary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives
show 4 more
Substituents
Alcohol / Amine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diphenylmethane / Hydrocarbon derivative
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
RS3K5YXV34
CAS number
13473-38-6
InChI Key
WPUKUEMZZRVAKZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H28NO3/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3/q+1
IUPAC Name
1-ethyl-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methylpiperidin-1-ium
SMILES
CC[N+]1(C)CCCC(C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. TITCK Product Information: PİPTALİN (pipenzolate) oral tablet [Link]
ChemSpider
4666
RxNav
33743
ChEBI
95178
ChEMBL
CHEMBL1619528
Wikipedia
Pipenzolate_bromide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suspension
Tablet, film coated
Solution / dropsOral
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000371 mg/mLALOGPS
logP-0.17ALOGPS
logP-0.62ChemAxon
logS-6ALOGPS
pKa (Strongest Acidic)11.05ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.14 m3·mol-1ChemAxon
Polarizability39.33 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created at June 23, 2017 20:49 / Updated at May 21, 2021 10:23